• Depot
  • Watchlist
  • Glocke
  • Handeln

    • Idorsia News

    1,897 CHF +8,90% +0,155 CHF
    In : 1,9398 € | 26.04.24 17:19:40 SIX Swiss Exchange aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2DTEB
    ISIN: CH0363463438
    US-Symbol: IDRSF
    Typ: Aktie

    Idorsia News

    26.04.24 - GlobeNewswire
    JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
    Ad hoc announcement pursuant to Art. 53 LR
    26.04.24 - GlobeNewswire
    JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
    Ad hoc announcement pursuant to Art. 53 LR
    23.04.24 - GlobeNewswire
    Idorsia publishes an invitation to a bondholder meeting
    Ad hoc announcement pursuant to Art. 53 LR
    23.04.24 - GlobeNewswire
    Idorsia publishes an invitation to a bondholder meeting
    Ad hoc announcement pursuant to Art. 53 LR
    17.04.24 - GlobeNewswire
    Idorsia publishes a Financial Status required for an upcoming bondholder meeting
    Ad hoc announcement pursuant to Art. 53 LR
    17.04.24 - GlobeNewswire
    Idorsia publishes a Financial Status required for an upcoming bondholder meeting
    Ad hoc announcement pursuant to Art. 53 LR
    11.04.24 - GlobeNewswire
    Idorsia takes steps to address short-term liquidity needs
    Ad hoc announcement pursuant to Art. 53 LR
    11.04.24 - GlobeNewswire
    Idorsia takes steps to address short-term liquidity needs
    Ad hoc announcement pursuant to Art. 53 LR
    22.03.24 - GlobeNewswire
    Idorsia thanks Guy Braunstein for his years of service as he retires
    Guy Braunstein, currently Chief Medical Officer and member of the Idorsia Executive Committee, to retire at the end of March 2024 Allschwil, Switzerland – March 22, 2024 Idorsia Ltd ...
    22.03.24 - GlobeNewswire
    Idorsia thanks Guy Braunstein for his years of service as he retires
    Guy Braunstein, currently Chief Medical Officer and member of the Idorsia Executive Committee, to retire at the end of March 2024 Allschwil, Switzerland – March 22, 2024 Idorsia Ltd ...
    20.03.24 - GlobeNewswire
    US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
    Ad hoc announcement pursuant to Art. 53 LR
    20.03.24 - GlobeNewswire
    US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
    Ad hoc announcement pursuant to Art. 53 LR
    18.03.24 - GlobeNewswire
    Idorsia and Viatris successfully close the transaction for the global research and development collaboration
    Ad hoc announcement pursuant to Art. 53 LR
    18.03.24 - GlobeNewswire
    Idorsia and Viatris successfully close the transaction for the global research and development collaboration
    Ad hoc announcement pursuant to Art. 53 LR
    28.02.24 - GlobeNewswire
    Idorsia and Viatris enter into a significant global research and development collaboration
    Ad hoc announcement pursuant to Art. 53 LR
    28.02.24 - GlobeNewswire
    Idorsia and Viatris enter into a significant global research and development collaboration
    Ad hoc announcement pursuant to Art. 53 LR
    10.01.24 - GlobeNewswire
    Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
    Ad hoc announcement pursuant to Art. 53 LR
    10.01.24 - GlobeNewswire
    Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
    Ad hoc announcement pursuant to Art. 53 LR
    03.11.23 - GlobeNewswire
    New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
    Allschwil, Switzerland – November 3, 2023
    03.11.23 - GlobeNewswire
    New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
    Allschwil, Switzerland – November 3, 2023

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »